Company news
Oxford Biodynamics Plc (LSE:OBD) news
Oxford Biodynamics Plc news releases on 6ix. Latest, Mar 1, 2022: PUBLICATION OF 2021 ANNUAL REPORT
Press releases — page 3
PUBLICATION OF 2021 ANNUAL REPORT
March 1, 2022
US launch of EpiSwitch® CiRT for oncology
February 25, 2022
Final Results
January 25, 2022
OBD updates on EpiSwitch CST and CiRT tests
December 17, 2021
Results of General Meeting
November 11, 2021
OBD raises £3.62 million
October 25, 2021
Change of Registered Office
September 28, 2021
Oxford BioDynamics awarded US FNIH Grant
August 31, 2021
New UK facilities to support expanded strategy
April 9, 2021
OBD signs agreement with Agilent Technologies
March 31, 2021
US launch of EpiSwitch® COVID-19 Severity Test
March 23, 2021
Results published of biomarker discovery program
March 17, 2021
Publication of 2020 Annual Report and AGM date
February 23, 2021
Directorate Change
December 30, 2020
Oxford BioDynamics to expand strategic focus
December 15, 2020
Appointment of Chairman
December 14, 2020
Strategic partnership with Boca Biolistics
November 2, 2020
Disease severity program for COVID-19 advances
October 28, 2020
Interim results for six months ended 31 March 2020
June 16, 2020
Board transition
June 3, 2020
Business update and notice of interim results
May 21, 2020
Biomarker platform COVID-19 update
April 30, 2020
PDMR Dealing - Replacement
April 2, 2020
PDMR Shareholding
March 20, 2020
Director Dealing
March 19, 2020
Board restructure to support future growth
March 16, 2020
Correction - PDMR Dealing
March 2, 2020
OBD to present at BioTech Pharma Summit
February 20, 2020
Publication of Annual Report and Notice of AGM
January 23, 2020
EpiSwitch used in diagnosis of canine lymphoma
January 15, 2020
OBD enters into master service agreement
December 20, 2019
Prelim Results for year ended 30 September 2019
December 10, 2019
OBD's EpiSwitch featured in presentations
November 8, 2019
OBD appoints Iain McInnes to Advisory Board
October 30, 2019
First patient enrolled in ALS biomarker study
October 25, 2019
OBD to present at MAC10
July 19, 2019
OBD appoints Dr Bartu Ahiska
June 13, 2019
Board Transition
May 31, 2019
Interim Results for 6 months ended 31 March 2019
May 28, 2019
OBD to present at China BIO Conference
May 8, 2019
OBD joins ALS Biomarker study sponsored by MTPA
May 3, 2019
Notice of Interim Results
April 29, 2019
Queen's Award for Enterprise
April 23, 2019
Board Appointments
April 5, 2019
OBD US subsidiary and commercial lead
April 2, 2019
OBD joins Imperial in a prostate cancer trial
March 19, 2019
Notice of results for year ended 30 Sept 2018
November 23, 2018
Collaboration into identifying diagnosis of Autism
November 12, 2018
OBD signs fifth collaboration agreement
November 8, 2018
Study published in Faculty of 1000 Research
November 7, 2018